The immunosuppressive regimen of cydosporine A reduced or withdrawn In the HBV-DNA positive kidney transplanted patients.
- VernacularTitle:减少或撤除环孢素A的免疫抑制方案在HBV-DNA阳性肾移植患者中的应用
- Author:
Dong CHEN
;
Weijie ZHANG
;
Zhishui CHEN
;
Fanjun ZEN
;
Bin LIU
;
Lai WEI
;
Shi CHEN
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
HBV-DNA;
Cyclosporin A
- From:
Clinical Medicine of China
2008;24(11):1158-1160
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the immunosuppressive regimen of cyclosporine A(CsA) reduced or withdrawn in the HBV-DNA positive kidney transplanted patients. Methods The program of 64 kidney transplanted patients with HBV-DNA positive from Jan,2004 to Dec,2007 were analyzed, the patients were divided into 3 groups ①CsA + MMF group(A group) ;②FK506 + MMF group(B group) ;③low dose of CsA + SRL group(C group). All the patients received entecavir to resist HBV replication and were followed up for acute rejection incidence,liverfunc- tion and HBV-DNA test for 6 months. Results There was no significant difference in 3 groups about acute rejection incidence rate. Liver dysfunction took place in 12 patients of A group (80%) ,8 patients(53%) in A group HBV-DNA became negative; 5 patients (20%) in B group appeared the liver dysfunction, HBV-DNA became negative in 18 patients(75%). 4 patients in C group(16%) appeared liver dysfunction sHBV-DNA was negative in 18 patients (72%) of C group. Conclusion It was safe and efficient for the immunosuppressive regimen of cyclosporin A re-duced or withdrawn in the HBV-DNA positive kidney transplanted patients,not increasing the incidence of acute re-jection and aggratating the liver injury.
